BACKGROUND AND PURPOSE: Patients with intracranial atherosclerotic disease have a 3.6% to 22% annual risk of stroke. In this study, we sought to evaluate the natural history and prognosis of patients with symptomatic intracranial atherosclerotic disease who received medical therapy versus percutaneous transluminal angioplasty and stenting (PTAS) at our institution. METHODS: Charts of all patients with symptomatic intracranial atherosclerotic disease from July 2004 to September 2007 were reviewed and assessed for history of transient ischemic attack or stroke. Patients were either treated with "best medical therapy" (Medical Therapy Group) or PTAS plus antiplatelet agents (PTAS Group) and followed prospectively. A favorable outcome was defined as the absence of transient ischemic attacks, strokes, or vascular death; modified Rankin Scale of < or =3; and no endovascular reintervention of symptomatic in-stent restenosis. RESULTS: One hundred eleven patients fulfilled entry criteria, with 58 (52.3%) and 53 patients (47.7%) enrolled in the Medical Therapy and PTAS Groups, respectively. Thirty-eight patients of the Medical Therapy Group (65.5%) had a favorable outcome compared with 37 patients of the PTAS Group (69.8%). Combined ischemic end point data for the occurrence of transient ischemic attack, stroke, and vascular death was similar with 14 (24%) events in the Medical Therapy Group versus 15 (28.3%) events in the PTAS Group. CONCLUSIONS: Overall, the combined ischemic end point was the same in the Medical Therapy and PTAS Groups.
BACKGROUND AND PURPOSE:Patients with intracranial atherosclerotic disease have a 3.6% to 22% annual risk of stroke. In this study, we sought to evaluate the natural history and prognosis of patients with symptomatic intracranial atherosclerotic disease who received medical therapy versus percutaneous transluminal angioplasty and stenting (PTAS) at our institution. METHODS: Charts of all patients with symptomatic intracranial atherosclerotic disease from July 2004 to September 2007 were reviewed and assessed for history of transient ischemic attack or stroke. Patients were either treated with "best medical therapy" (Medical Therapy Group) or PTAS plus antiplatelet agents (PTAS Group) and followed prospectively. A favorable outcome was defined as the absence of transient ischemic attacks, strokes, or vascular death; modified Rankin Scale of < or =3; and no endovascular reintervention of symptomatic in-stent restenosis. RESULTS: One hundred eleven patients fulfilled entry criteria, with 58 (52.3%) and 53 patients (47.7%) enrolled in the Medical Therapy and PTAS Groups, respectively. Thirty-eight patients of the Medical Therapy Group (65.5%) had a favorable outcome compared with 37 patients of the PTAS Group (69.8%). Combined ischemic end point data for the occurrence of transient ischemic attack, stroke, and vascular death was similar with 14 (24%) events in the Medical Therapy Group versus 15 (28.3%) events in the PTAS Group. CONCLUSIONS: Overall, the combined ischemic end point was the same in the Medical Therapy and PTAS Groups.
Authors: Ralph L Sacco; Robert Adams; Greg Albers; Mark J Alberts; Oscar Benavente; Karen Furie; Larry B Goldstein; Philip Gorelick; Jonathan Halperin; Robert Harbaugh; S Claiborne Johnston; Irene Katzan; Margaret Kelly-Hayes; Edgar J Kenton; Michael Marks; Lee H Schwamm; Thomas Tomsick Journal: Stroke Date: 2006-02 Impact factor: 7.914
Authors: Scott E Kasner; Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano; Harry J Cloft Journal: Circulation Date: 2006-01-23 Impact factor: 29.690
Authors: Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Scott E Kasner; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano Journal: N Engl J Med Date: 2005-03-31 Impact factor: 91.245
Authors: David Fiorella; Elad I Levy; Aquilla S Turk; Felipe C Albuquerque; David B Niemann; Beverly Aagaard-Kienitz; Ricardo A Hanel; Henry Woo; Peter A Rasmussen; L Nelson Hopkins; Thomas J Masaryk; Cameron G McDougall Journal: Stroke Date: 2007-02-08 Impact factor: 7.914
Authors: E I Levy; R Mehta; R Gupta; R A Hanel; A J Chamczuk; D Fiorella; H H Woo; F C Albuquerque; T G Jovin; M B Horowitz; L N Hopkins Journal: AJNR Am J Neuroradiol Date: 2007-05 Impact factor: 3.825
Authors: Michael P Marks; Joan C Wojak; Firas Al-Ali; Mahesh Jayaraman; Mary L Marcellus; John J Connors; Huy M Do Journal: Stroke Date: 2006-02-23 Impact factor: 7.914
Authors: Richard du Mesnil de Rochemont; Bernd Turowski; Martin Buchkremer; Matthias Sitzer; Friedhelm E Zanella; Joachim Berkefeld Journal: Radiology Date: 2004-04 Impact factor: 11.105
Authors: R Gupta; H C Schumacher; S Mangla; P M Meyers; H Duong; A G Khandji; R S Marshall; J P Mohr; J Pile-Spellman Journal: Neurology Date: 2003-12-23 Impact factor: 9.910
Authors: M D Alexander; P M Meyers; J D English; T R Stradford; S Sung; W S Smith; V V Halbach; R T Higashida; C F Dowd; D L Cooke; S W Hetts Journal: AJNR Am J Neuroradiol Date: 2014-03-27 Impact factor: 3.825
Authors: Ricardo J Komotar; Christopher P Kellner; Daniel M Raper; Dorothea Strozyk; Randall T Higashida; Philip M Meyers Journal: World J Radiol Date: 2010-05-28
Authors: Edgar A Samaniego; Amir Shaban; Santiago Ortega-Gutierrez; Jorge A Roa; David M Hasan; Colin Derdeyn; Biyue Dai; Harold Adams; Enrique Leira Journal: Stroke Vasc Neurol Date: 2019-07-30
Authors: Rezao Mohammadian; Ali Pashapour; Ehsan Sharifipour; Reza Mansourizadeh; Farideh Mohammadian; Ali Akbar Taher Aghdam; Mohammad Mousavi; Farhad Dadras Journal: Cerebrovasc Dis Extra Date: 2012-11-01